EGFR and non-small cell lung carcinoma: EGFR tyrosine kinase inhibitors (TKIs) are the standard first‐line treatment option for advanced or metastatic non‐small cell lung carcinoma (NSCLC) patients harboring TKI‐sensitive EGFR mutations, and confer a greater progression‐free survival (PFS) benefit than treatment with cytotoxic chemotherapy.8, 9, 10, 11, 12